Home > Insider Trading > Filing (0000899243-22-001657)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1827087	Vigil Neuroscience Inc.	VIGL	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1855502	Vida Ventures Gp Iii, L.l.c.	40 Broad Street, Suite 201 Boston MA 02109	No	No	Yes	No
1855503	Vida Ventures Iii-A, L.p.	40 Broad Street, Suite 201 Boston MA 02109	No	No	Yes	No
1855504	Vida Ventures Iii, L.p.	40 Broad Street, Suite 201 Boston MA 02109	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-11	3,333,245	$0.00	3,333,245	No	4	C	Indirect	By Vida Ventures III, L.P.
Common Stock	Acquisiton	2022-01-11	7,684	$0.00	7,684	No	4	C	Indirect	By Vida Ventures III-A, L.P.
Common Stock	Acquisiton	2022-01-11	1,671,148	$14.00	5,004,393	No	4	P	Indirect	By Vida Ventures III, L.P.
Common Stock	Acquisiton	2022-01-11	3,852	$14.00	11,536	No	4	P	Indirect	By Vida Ventures III-A, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Vida Ventures III, L.P.
No	4	C	Indirect	By Vida Ventures III-A, L.P.
No	4	P	Indirect	By Vida Ventures III, L.P.
No	4	P	Indirect	By Vida Ventures III-A, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2022-01-11	9,243,756	$0.00	3,333,245	$0.00
Common Stock	Series B Preferred Stock	Disposition	2022-01-11	21,310	$0.00	7,684	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.
The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
On January 11, 2022, Vida III purchased 1,671,148 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering.
On January 11, 2022, Vida III-A purchased 3,852 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering.